Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05266456 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults
A Phase 1 study, sponsored by Vaxcyte.
- Completed
- Registry status
- Phase 1
- Development phase
- 835
- Enrollment target
NCT05266456 is a Phase 1 study that has completed, run by Vaxcyte. The registered enrollment target is 835 participants.
The verdict
NCT05266456, a Phase 1 study, has completed, sponsored by Vaxcyte.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 835 participants
- Enrollment target
Study Summary
The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 18 to 49 years of age in Phase 1. The Phase 2 will evaluate the safety, tolerability, and immunogenicity of a single injection of VAX-24 at 3 dose levels compared to PCV20 in adults aged 50 to 64 years of age in Phase 2.
Interventions
- BIOLOGICAL 20 valent pneumococcal conjugate vaccine
- BIOLOGICAL 24 valent pneumococcal conjugate vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 835 participants |
| Start Date | 2022-02-22 |
| Est. Completion | 2023-01-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05266456
The ClinicalTrials.gov registry entry for NCT05266456 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 835 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vaxcyte, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 20 valent pneumococcal conjugate vaccine is the first listed.
NCT05266456 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05266456 about?
NCT05266456 is a clinical study titled "Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults". The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 18 to 49 years of age in Phase 1. The Phase 2 will evaluate the safety, tolerability, and immunogenicity of a single injection of VAX-24 at...
What is the current status of trial NCT05266456?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 835 participants. The study started on 2022-02-22. Estimated completion is 2023-01-10.
What interventions are being tested in trial NCT05266456?
The interventions under investigation include: 20 valent pneumococcal conjugate vaccine (BIOLOGICAL), 24 valent pneumococcal conjugate vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05266456?
This trial is sponsored by Vaxcyte, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.